Loading...

Home
ETF
BIAF

BIAF

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BIAF News

BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth

Mar 23 2026stocktwits

BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge

Mar 23 2026stocktwits

bioAffinity Technologies Launches New Lung Cancer Test Case Study

Mar 17 2026NASDAQ.COM

BioAffinity Technologies Shares Surge 20% on Positive CyPath Lung Test Results

Mar 17 2026stocktwits

bioAffinity Technologies 2025 Financial Overview

Mar 13 2026seekingalpha

bioAffinity Technologies Stock Soars on Strong CyPath Lung Results

Mar 13 2026Benzinga

bioAffinity Technologies Shares Surge 72% on Lung Cancer Study Announcement

Mar 13 2026NASDAQ.COM

U.S. Stocks Rise in Morning Trade Amid Economic Slowdown

Mar 13 2026Benzinga

bioAffinity Technologies Reports 2025 Financial Highlights

Mar 13 2026Newsfilter

BIOAFFINITY TECHNOLOGIES REPORTS RECORD REVENUE AND UNIT SALES FOR CYPATH® LUNG, ITS LEADING LUNG CANCER DIAGNOSTIC, IN 2025

Mar 13 2026moomoo

bioAffinity Technologies Unveils New Diagnostic Advances for Asthma Treatment

Mar 03 2026Newsfilter

CyPath® Lung Test Supports Noninvasive Surveillance Strategy

Feb 19 2026Newsfilter

bioAffinity Showcases CyPath® Lung Cancer Detection Technology with 92% Sensitivity

Dec 03 2025Newsfilter

bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume

Nov 05 2025Newsfilter

bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations

Oct 09 2025Newsfilter

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 09 2025PRnewswire